MicroPort Orthopedics Complete Profemur Gladiator Hip System Now Available

MicroPort Orthopedics announced the availability of its Profemur® Gladiator® HA Collared Stem and Profemur® Gladiator® Cemented Collared Stem.

Combined with its current Profemur® Gladiator® Plasma Stem, the Gladiator® Hip Stem System is now complete, offering  a wide range of indications in the treatment of both high demand total hip arthroplasties and low demand fracture patients.
Designed for primary hip replacement surgery, the Profemur® Gladiator® Hip Stems all offer a triple wedge tapered design with distinct geometry. The hip stem is designed with a reduced lateral shoulder convenient for tissue-sparing techniques, making it perfectly suited to be used with MicroPort’s disruptive innovation through the Anterior Path® surgical approach.  The Profemur® line of Hip Stems gives surgeons the versatility to address their patients’ needs with one set of instruments in this truly comprehensive system.
“By allowing surgeons to cater a femoral hip system to their preferred techniques, we have created a customizable hip system that is Simply Versatile™ in its ability to exceed the needs of each surgeon, designed to help our surgeons more effectively treat patients,” said Benny Hagag, President of MicroPort Orthopedics. “This customization to tissue-sparing techniques allows for streamlined preoperative planning, excellent patient outcomes1,2, and a quicker recovery3. The proof is in our patients.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.